Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations-Reference-Cited by-同舟云学术

Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

Published:2021-09-28 Issue:2 Volume:88 Page:858-864
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Voronova Veronika¹^ORCID,Cullberg Marie²^ORCID,Delff Philip³⁴,Parkinson Joanna²^ORCID,Dota Corina⁵,Schiavon Gaia⁶,Maroj Brijesh⁷,Rekić Dinko²,Cheung S. Y. Amy⁸⁹

Affiliation:

1. M&S Decisions LLC Moscow Russia

2. Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg Sweden

3. Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&D, AstraZeneca R&D Boston MA USA

4. Vertex Pharmaceuticals Boston MA USA

5. Cardiovascular Safety Center of Excellence Oncology R&D, AstraZeneca R&D Gothenburg Sweden

6. Late Development Oncology Oncology R&D, AstraZeneca R&D Cambridge UK

7. Patient Safety Oncology, Global Medicines Development AstraZeneca R&D Cambridge UK

8. Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&D, AstraZeneca R&D Cambridge UK

9. Certara Princeton NJ USA

Funder

AstraZeneca Pharma Poland

Institute of Cancer Research

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15006

Reference32 articles.

1. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR

2. Targeting PI3K/Akt/mTOR Signaling in Cancer

3. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

4. Comprehensive molecular portraits of human breast tumours

5. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses;Pharmacology Research & Perspectives;2024-03-06

2. Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole;Clinical Pharmacology in Drug Development;2023-07-14

3. Dostarlimab, an anti‐programmed death‐1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration‐QT analysis;British Journal of Clinical Pharmacology;2023-03-20

4. “The emerging role of capivasertib in breast cancer”;The Breast;2022-06